Concordance between molecular and phenotypic testing of mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 1932-1937

  Yakrus, Mitchell A ^a   Driscoll, Jeffrey ^a   Lentz, Allison J ^a   Sikes, David ^a   Hartline, Denise ^a   Metchock, Beverly ^a   Starks, Angela M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BIOINFORMATICS; DATA ANALYSIS; GENE; HEALTH SURVEY; HUMAN; INHA GENE; KATG GENE; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RPOB GENE; UNITED STATES; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPING TECHNIQUES; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS; UNITED STATES;

EID: 84901660364     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00417-14     Document Type: Article

References (12)

1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O?Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. 2003. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Crit. Respir. Care Med. 167:603-662. http://dx.doi.org/10. 1164/rccm.167.4.603.
2. Campbell PJ, Morlock GP, Sikes DR, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041. http://dx.doi.org/10.1128/AAC.01550- 10.
3. Driscoll J, Lentz A, Sikes D, Metchock B. 2010. The first month of a new diagnostic service for the molecular detection of MDR and XDR tuberculosis. Am. J. Respir. Crit. Care Med. 181:A2259. http://www.atsjournals.org/doi/abs/10. 1164/ajrccm-conference.2010.181.1-Meeting Abstracts.A2259.
4. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; approved standard-2nd ed, p 1-64. CLSI document M24A2E, vol 31, no 5. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Van Duen A, Barrera I, Bastian L, Fattorini H, Hoffman KM, Kam L, Rigouts S, R?sch-Gerdes S, Wright A. 2009. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J. Clin. Microbiol. 47:3501-3506. http://dx.doi.org/10.1128/JCM.01209-09.
6. Van Ingen J, Aarnoutse R, de Vries G, Boeree MJ, van Soolingen D. 2011. Low-level rifampin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int. J. Tuberc. Lung Dis. 15:990-992. http://dx.doi.org/10.5588/ijtld.10.0127.
7. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E. Uwizeye C, deJong B, Van Duen A. 2013. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis with specific rpoBmutation. J. Clin. Microbiol. 51:2641-2645. http://dx.doi.org/10.1128/JCM.02741-12.
8. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhoff JC. 2012. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J. Clin. Microbiol. 50:1233-1239. http://dx.doi.org/10.1128/JCM.06479-11.
9. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, Lewis CA, Freeman JT. 2011. Clinical failures associated with rpoB mutations in phenotypically occult multidrug resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 16:216-220. http://dx.doi.org/10.5588/ijtld.11.0178.
10. Van Duen A, Maug AKG, Bola V, Lebeke R, Hossain, A, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, deJong BC. 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J. Clin. Microbiol. 51:2633-2640. http://dx.doi.org/10.1128/JCM.00553-13.
11. CDC. 2013. Availability of an assay for detecting Mycobacterium tuberculosis including rifampin-resistant strains and recommendations for its use. MMWR Morb. Mortal. Wkly. Rep. 62:821-824.
12. Smith SE, Kurbatova JS, Cavanaugh JP, Cegielski JP. 2012. Global isoniazid resistance patterns in rifampin-resistant and rifampin susceptible tuberculosis. Int. J. Tuberc. Lung Dis. 16:203-205. http://dx.doi.org/10.5588/ ijtld.11.0445.